Atlas Trials

Recurrent Bladder Carcinoma

16 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Bladder Carcinoma

RecordFirmDate
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278)Rutgers, The State University of New Jersey2017-10-03
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations (NCT03047213)National Cancer Institute (NCI)2017-08-24
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer (NCT02808143)Northwestern University2017-02-10
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer (NCT02767921)University of Southern California2016-08-02
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319)Mayo Clinic2016-01-01
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer (NCT02437370)University of California, Davis2015-09-01
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060)National Cancer Institute (NCI)2015-08-17
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery (NCT02169284)National Cancer Institute (NCI)2014-10-01
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer (NCT01938573)University of Washington2013-10-01
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533)National Cancer Institute (NCI)2012-08-03
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820)Roswell Park Cancer Institute2012-03-01
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer (NCT01050504)University of Washington2009-08-01
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer (NCT00118040)National Cancer Institute (NCI)2005-06-24
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy (NCT00072137)National Cancer Institute (NCI)2003-10-01

Track Recurrent Bladder Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.